Bimekizumab (Bimzelx®). HTA ID: 21052

Assessment Status Rapid Review complete
HTA ID 21052
Drug Bimekizumab
Brand Bimzelx®
Indication Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Assessment Process
Rapid review commissioned 15/11/2021
Rapid review completed 07/01/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of bimekizumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.

The HSE has approved reimbursement following confidential price negotiations; June 2023